What Are the Known Facts About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Drug Safety Concerns

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that new medications can reveal unexpected side effects only after widespread use. This page reviews the current medical understanding of the potential connection between Ozempic and delayed gastric emptying.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its mechanism of action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Among the most serious potential complications is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent nausea and vomiting, often with postprandial fullness and bloating. Diagnostic confirmation usually requires gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can significantly impair quality of life and may lead to malnutrition, dehydration, and electrolyte disturbances. Ozempic's pharmacology directly relates to the risk of gastroparesis. The drug slows gastric emptying as part of its glucose-lowering effect, but this action can become pathological in some patients. Evidence from placebo-controlled trials shows that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, versus 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Risk Factors for Gastroparesis

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's effect on the vagus nerve and enteric nervous system. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation by semaglutide can inhibit gastric motility. This effect is dose-dependent and may persist even after drug discontinuation, leading to chronic gastroparesis in susceptible individuals. The reported gastrointestinal adverse reactions with a frequency of less than 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, making diagnosis challenging. Risk anchors for settlement-related considerations include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but it does not address the potential for prolonged gastric emptying dysfunction. This gap in warning may be relevant for patients who developed gastroparesis after using Ozempic, as they may not have been adequately informed of the risk.

Settlement Criteria and Legal Considerations

Settlement-related considerations for affected patients involve documenting the timeline between exposure to Ozempic and the onset of gastroparesis symptoms. Patients who experienced nausea, vomiting, or other gastrointestinal symptoms during dose escalation and later developed chronic gastroparesis may have a stronger claim. The evidence shows that gastrointestinal adverse reactions are most common during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but the progression to gastroparesis may occur over weeks to months. Medical records should include dates of Ozempic initiation, dose changes, symptom onset, and diagnostic tests such as gastric emptying studies. The timeline between exposure and documented harm is critical for establishing causation. Patients who developed gastroparesis after starting Ozempic and who had no prior history of gastric motility disorders may have a plausible link. The discontinuation rates due to gastrointestinal adverse reactions (3.1% for 0.5 mg and 3.8% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) suggest that a subset of patients experiences severe enough symptoms to stop treatment, which could be a precursor to gastroparesis. In summary, the evidence indicates that Ozempic is associated with a range of gastrointestinal adverse reactions, including those that may lead to or mimic gastroparesis. The adequacy of warnings is a key risk factor for litigation, as the label does not explicitly mention gastroparesis. Patients affected by this condition should seek legal counsel to evaluate their individual circumstances, including the timing of exposure and the severity of harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the Ozempic gastroparesis settlement about?

The Ozempic gastroparesis settlement involves legal claims by patients who developed gastroparesis after using Ozempic. Settlement criteria require documented exposure to Ozempic, a confirmed gastroparesis diagnosis, and evidence linking the condition to the medication. Patients may be eligible for compensation if they experienced severe gastrointestinal symptoms and the drug's warnings were inadequate.

How can I determine if I am eligible for the Ozempic gastroparesis settlement?

Eligibility typically requires proof of Ozempic use, a medical diagnosis of gastroparesis confirmed by gastric emptying scintigraphy, and a timeline showing symptoms developed after starting the medication. Medical records should document dose changes and symptom onset. Consulting with a legal professional specializing in pharmaceutical litigation is recommended to assess individual circumstances.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.